Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Abivax SA (ABVX)
Company Research
Source: GlobeNewswire
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trialThe Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026Abivax appointed Michael Nesrallah, MBA as Chief Commercial Officer, bringing extensive IBD leadership experience to support the Company’s next phase of growth; other key senior leadership hires made in Regulatory Affairs and Research to support continued advancements of its programsCash, cash equivalents and short-term investments of €530.4M as of December 31, 2025; cash runway into Q4 2027Abivax’s Annual General Meeting (“AGM”) to be held May 11, 2026, and the Company expects to report its f
Show less
Read more
Impact Snapshot
Event Time:
ABVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABVX alerts
High impacting Abivax SA news events
Weekly update
A roundup of the hottest topics
ABVX
News
- Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory AgenciesGlobeNewswire
- 2 Healthcare Stocks That Could Soar Over the Next 5 Years [Yahoo! Finance]Yahoo! Finance
- Abivax (ABVX) had its price target raised by Barclays PLC from $142.00 to $148.00. They now have an "overweight" rating on the stock.MarketBeat
- Abivax (ABVX) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $160.00 price target on the stock.MarketBeat
- Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year [Yahoo! Finance]Yahoo! Finance